Top Health Tech Companies in London (370)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Galleri and total revenue have risen consistently, with full-year 2025 up 17% and U.S. Galleri up 26%, followed by Q1–Q2 2026 total revenue gains of 28% and 26% alongside 50% and 35% volume growth. This cadence, including Q4 2025 Galleri revenue up 31%, indicates sustained commercial momentum after the June 2024 spin‑off.
Strategic Partnerships: Channel and platform integrations such as Epic EHR and Quest Diagnostics, plus collaborations like Samsung for Asian commercialization, are expanding access and streamlining ordering. Additional distribution wins (e.g., Priority Health employer plans and digital health channels) reinforce multi‑channel penetration for Galleri.
Investor Backing & Capital Strength: The company reports a substantial cash balance (~$861.6M as of Q2 2026) and closed a $110M equity financing with Samsung, bolstering financial flexibility. Public listing post‑spin‑off further enhances capital‑markets access to fund trials and commercialization.
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere. With 46,000+ global team members, we have the opportunity to make a positive impact on healthcare in communities everywhere. Our team members are empowered to activate their careers through a collective of tools and resources designed to support individual career interests and...
Cencora's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue has risen across multiple periods, including fiscal 2025 up about 9% to roughly $321 billion and mid‑single‑digit year‑over‑year increases in fiscal 2026 quarters. Disclosures also note Q4 FY2025 revenue of $83.7 billion, up 5.9% year over year.
Profitability: Adjusted operating income and EPS expanded, with FY2025 adjusted EPS up 16% to $16.00 and Q2 FY2026 GAAP EPS rising to $8.40 alongside a raised full‑year adjusted EPS outlook to about $17.70–$17.90. Management also indicated double‑digit adjusted operating income growth expected for FY2026.
Resilient & Sustainable Growth: Momentum spans FY2023–FY2026 to date, with revenue progressing from about $262 billion (FY2023) to $294 billion (FY2024) to $321 billion (FY2025) and continued gains in 2026. Portfolio refocusing and acquisitions in specialty care (e.g., Retina Consultants of America, OneOncology) are described as engines supporting ongoing expansion and margin mix.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.
Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.
Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Top line is described as expanding steadily in recent years, with continued growth expected. Separate reporting cites roughly $500 million in annual revenue and rapid momentum, even as exact figures vary.
Healthy Cash Flow: Cash generation has improved enough for a late‑2025 credit rating upgrade, with projections to produce over $100 million in free cash flow within the next 12–24 months. Leverage is expected to trend down alongside strong margins.
Customer Loyalty & Retention: Retention is characterized as consistently high with net expansion of spend, signaling durable relationships and effective cross‑sell within the installed base. A sizable customer count (over 4,000 organizations) supports stickiness across regions.
ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 15,000+ employees in over 40 offices worldwide.
ZS's Top Stability & Growth Strengths
Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.
Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.
Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Market Expansion: International partnerships across the UK, Germany, and Japan—culminating in a first Scottish agreement in 2026—are described as tripling the network in 2025 and adding nearly 70% ex‑U.S. growth in 2026. These moves indicate a materially broader geographic footprint for evidence generation.
Strategic Partnerships: Collaborations with organizations such as NHS Greater Glasgow and Clyde, Quest Diagnostics, Abbott, TailorMed, and Unicancer reflect deepening integration at the point of care and with research stakeholders. These relationships suggest expanding routes to market and data acquisition.
Product Line Growth: New offerings like Flatiron Telescope, AI‑powered oncology datasets, and an AI data‑quality/validation framework signal active investment in products and capabilities. Conference acceptances at ISPOR/ASCO/WCLC in 2026 further underscore ongoing commercialization and scientific engagement.
At Synaptiq Health, we are deeply passionate about advancing life-changing therapies and services. As a collective of specialised agencies, including Emotive, Initiate, and Beyond PR, we bring together unparalleled expertise across Medical Communications, Market Access & HEOR, and PR & Advocacy. Our dedicated teams partner with top global pharmaceutical, biopharma, and biotechnology companies, as well as influential medical societies and health...
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and...
Sanofi's Top Stability & Growth Strengths
Strong Revenue Growth: Sales growth is described as strong, with 2025 net sales up at constant exchange rates and Q4 showing further acceleration, indicating momentum into 2026.
Profitability: Earnings expansion is described as outpacing sales growth in 2025, and 2026 guidance indicates continued profitable expansion with EPS growing slightly faster than sales.
Product Line Growth: Newer launches are scaling rapidly, with notable growth in recent pharma launches and contributions from products beyond the flagship franchise, helping broaden growth drivers.
Introducing Log my Care – the platform for outstanding care management. We've witnessed first-hand how busy support workers are and the impact this has on the quality of care provided. Fewer people don't equal less work (if only!) This impact is felt across the industry, by society, and most importantly, by those in your care and their families. And that...
We are BOLDSCIENCE. We are a scientifically creative global medical communications agency. What exactly does that mean? It means our staff are made up of talented science communicators, artists, and curious disruptors, that collaborate to create impactful communication programs for pharmaceutical clients who need a compelling voice. We know what it takes to create brands, to start new conversations, to...
Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met...
Built by a team of experts who understand therapy, the way you do. isosconnect is a simple, safe software solution that keeps you connected to your clients. Built for Dietitians, Physiotherapists and Psychologists. Because people want easy access to Diet, Body and Mind solutions, and you are the experts!
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around...
Breezie is a tablet interface proven to engage seniors irrespective of their technical capabilities. Breezie helps seniors lead a happier, healthier and independent life as long as possible by keeping them socially connected and providing mental engagement with access to a wide range of content. It runs on an open platform that enables senior living providers to deliver their own...
The UK's leading wellness brands. We create revolutionary, world-first natural products
Medefer is a virtual healthcare provider to the NHS, using innovative technology to support early specialist-led patient care. This input leads to an improvement in the care pathway, shorter waiting times, increased Consultant capacity and reduced costs. To implement the service, Medefer has built a bespoke IT platform and created a robust governance process that safely tracks and monitors patients...
Inizio Evoke is a global health marketing, communications, and transformation platform unlocking growth through data-driven insights and human centricity. We are purpose-built to make Health more human™. With core expertise and specialty brands in Marketing, Comms, Transformation, Access, and Media, we serve as a premier partner for the world's most ambitious healthcare organizations. Inizio Evoke is an Inizio company. Inizio...
Inizio Evoke's Top Stability & Growth Strengths
Strong Market Position & Advantage: Repeated Top 10 placement in MM+M’s Agency 100 (including #9 in 2025 based on 2024 revenue) and finalist recognition for Healthcare Network of the Year signal durable top-tier standing. Industry lists and client accolades indicate competitiveness even if not the largest by revenue.
Innovation-Driven Growth: Investments in AI-enabled solutions (e.g., Predictev™ and Cognitev™) and creation of an EVP role for AI Transformation demonstrate a clear push to scale data- and technology-led offerings. The 2024 unification under one platform strengthens omnichannel and audience intelligence capabilities.
Future-Ready Strategy: A unified model spanning marketing, communications, transformation, access, and media within the broader Inizio ecosystem positions delivery across the commercialization lifecycle. Consistent rankings and strategic hires point to preparedness for re-acceleration as integration benefits compound.
CoMind is revolutionising brain healthcare with its non-invasive technology, redefining how the brain is measured and treated to optimise patient outcomes across the care continuum. Based in London, CoMind designs and manufactures a groundbreaking approach to brain monitoring, which provides a multidimensional view of brain activity using light. It enhances patient safety, improves healthcare economics, and improves clinical outcomes. Their...
32Co is the future of collaborative healthcare- we're revolutionizing access to specialized healthcare services by connecting general clinicians with a network of specialists. Inspired by the telemedicine sector, 32Co's platform facilitates collaboration between generalist and specialist clinicians, offering patients the best of both worlds—high-quality clinical care delivered conveniently through their local provider. Our unique model scales specialist expertise beyond the...
.png)





























